The use of mitoxantrone plus cyclophosphamide as first-line treatment of metastatic breast cancer

W. R. Bezwoda, C. Hesdorffer

Research output: Contribution to journalArticle

Abstract

Thirty-two patients with metastatic breast cancer who had not received prior chemotherapy for metastatic disease were entered into a trial of mitoxantrone 12 mg/m2 plus cyclophosphamide 600 mg/m2 given at three weekly intervals. Thirty-one patients are eligible for assessment. Response was seen in 65% (4/31 complete regression; 16/31 partial regression). Median duration of response was 6 months and median duration of survival was 10 months. Mitoxantrone + cyclophosphamide appears to be an active combination in treatment of metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)1621-1624
Number of pages4
JournalCancer
Volume58
Issue number8
StatePublished - 1986
Externally publishedYes

Fingerprint

Mitoxantrone
Cyclophosphamide
Breast Neoplasms
Drug Therapy
Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The use of mitoxantrone plus cyclophosphamide as first-line treatment of metastatic breast cancer. / Bezwoda, W. R.; Hesdorffer, C.

In: Cancer, Vol. 58, No. 8, 1986, p. 1621-1624.

Research output: Contribution to journalArticle

Bezwoda, WR & Hesdorffer, C 1986, 'The use of mitoxantrone plus cyclophosphamide as first-line treatment of metastatic breast cancer', Cancer, vol. 58, no. 8, pp. 1621-1624.
Bezwoda, W. R. ; Hesdorffer, C. / The use of mitoxantrone plus cyclophosphamide as first-line treatment of metastatic breast cancer. In: Cancer. 1986 ; Vol. 58, No. 8. pp. 1621-1624.
@article{cdbfbff7a62d4e4b94352ffca3187706,
title = "The use of mitoxantrone plus cyclophosphamide as first-line treatment of metastatic breast cancer",
abstract = "Thirty-two patients with metastatic breast cancer who had not received prior chemotherapy for metastatic disease were entered into a trial of mitoxantrone 12 mg/m2 plus cyclophosphamide 600 mg/m2 given at three weekly intervals. Thirty-one patients are eligible for assessment. Response was seen in 65{\%} (4/31 complete regression; 16/31 partial regression). Median duration of response was 6 months and median duration of survival was 10 months. Mitoxantrone + cyclophosphamide appears to be an active combination in treatment of metastatic breast cancer.",
author = "Bezwoda, {W. R.} and C. Hesdorffer",
year = "1986",
language = "English (US)",
volume = "58",
pages = "1621--1624",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - The use of mitoxantrone plus cyclophosphamide as first-line treatment of metastatic breast cancer

AU - Bezwoda, W. R.

AU - Hesdorffer, C.

PY - 1986

Y1 - 1986

N2 - Thirty-two patients with metastatic breast cancer who had not received prior chemotherapy for metastatic disease were entered into a trial of mitoxantrone 12 mg/m2 plus cyclophosphamide 600 mg/m2 given at three weekly intervals. Thirty-one patients are eligible for assessment. Response was seen in 65% (4/31 complete regression; 16/31 partial regression). Median duration of response was 6 months and median duration of survival was 10 months. Mitoxantrone + cyclophosphamide appears to be an active combination in treatment of metastatic breast cancer.

AB - Thirty-two patients with metastatic breast cancer who had not received prior chemotherapy for metastatic disease were entered into a trial of mitoxantrone 12 mg/m2 plus cyclophosphamide 600 mg/m2 given at three weekly intervals. Thirty-one patients are eligible for assessment. Response was seen in 65% (4/31 complete regression; 16/31 partial regression). Median duration of response was 6 months and median duration of survival was 10 months. Mitoxantrone + cyclophosphamide appears to be an active combination in treatment of metastatic breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0022481387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022481387&partnerID=8YFLogxK

M3 - Article

C2 - 3756786

AN - SCOPUS:0022481387

VL - 58

SP - 1621

EP - 1624

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -